The BIOSECURE Act, China Decoupling, and Supply Chain Reshoring

Introduction

The BIOSECURE Act, signed into law in December 2025 as part of the National Defense Authorization Act (NDAA), represents the most significant regulatory intervention in the global biopharma supply chain in decades. The legislation reflects broader US-China decoupling dynamics but has specific, actionable implications for healthcare M&A, CDMO valuations, and the competitive positioning of outsourcing providers worldwide.

The Act prohibits US government agencies (including the Department of Defense, NIH, and agencies that fund healthcare research) from contracting with companies that use biotechnology equipment or services from designated "biotechnology companies of concern." The practical scope extends well beyond direct government contracts: companies receiving federal research funding, government healthcare programs, and federally funded clinical trials are all potentially in scope.

Biotechnology Company of Concern

A designation under the BIOSECURE Act for foreign biotechnology companies that are determined to pose a national security risk, particularly through potential transfer of US genomic data, proprietary drug manufacturing processes, or clinical trial data to foreign governments. While no companies have been formally designated as of early 2026, the legislation was drafted with specific Chinese companies in mind, particularly WuXi AppTec (CRO services), WuXi Biologics (CDMO services), BGI Group (genomics), and Complete Genomics. Designation triggers the prohibition on US government contracts with any entity that uses the designated company's services.

The 5-year transition period (through December 2030) provides existing customers time to shift manufacturing and development activities. However, industry behavior has already changed: multiple biopharma companies began diversifying away from WuXi and other Chinese outsourcing providers in 2024-2025, even before the Act was signed, creating what industry participants describe as a "de facto BIOSECURE effect" that preceded the legal requirement.

The BIOSECURE Act's impact on the CRO/CDMO landscape creates clear winners and losers.

Winners: Western CRO/CDMO companies with capacity to absorb redirected demand. Samsung Biologics, Lonza, Catalent (now Novo-owned), FUJIFILM Diosynth, and Thermo Fisher's pharma services division are primary beneficiaries. Indian CRO/CDMO companies (Biocon, Syngene, Piramal) are also positioned to capture share. The estimated $24.86 billion in reshoring investment creates a multi-year capacity expansion cycle.

Losers: Chinese outsourcing providers face contract losses and growth deceleration. WuXi AppTec and WuXi Biologics have already seen revenue growth slow in their Western client segments. Biopharma companies that had concentrated outsourcing relationships with Chinese providers face cost increases and timeline disruption during the transition period.

The BIOSECURE Act is directly driving M&A activity in several categories. CDMO capacity acquisitions by both strategic and financial buyers are accelerating as companies compete for manufacturing capacity that can absorb redirected demand from Chinese providers. The Novo/Catalent **$16.5 billion** transaction, while primarily driven by GLP-1 capacity needs, also positioned Novo with BIOSECURE-compliant manufacturing capabilities.

PE firms are investing in greenfield and brownfield CDMO capacity expansion, particularly for biologics manufacturing (mammalian cell culture, fill-finish) where the capacity constraints are most acute. CRO M&A is also active as sponsors build integrated platforms that can offer BIOSECURE-compliant end-to-end drug development services.

This concludes the Market Intelligence section. The final section covers interviewing for healthcare IB, teaching candidates how to present the knowledge from this guide in interview settings.